A prognostic score for acute graft-versus-host disease based on biomarkers: A multicentre study

The Lancet Haematology

Volumn 2, Issue 1, 2015, Pages e21-e29

  Levine, John E ^a   Braun, Thomas M ^a   Harris, Andrew C ^a   Holler, Ernst ^b   Taylor, Austin ^a,c   Miller, Holly ^a   Magenau, John ^a   Weisdorf, Daniel J ^d   Ho, Vincent T ^e   Bolaños Meade, Javier ^f   Alousi, Amin M ^g   Ferrara, James L M ^a,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c MOUNT SINAI HOSPITAL   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CALCINEURIN INHIBITOR; METHYLPREDNISOLONE; REG 3 ALPHA PROTEIN; ST2 CARDIAC BIOMARKER; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALGORITHM; ARTICLE; ASSESSMENT OF HUMANS; CLINICAL TRIAL; DISEASE SEVERITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; ADOLESCENT; ADVERSE EFFECTS; AGED; ALLOTRANSPLANTATION; BLOOD; CHILD; CONTROLLED STUDY; GRAFT VS HOST DISEASE; INFANT; NEWBORN; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS; CHILD; CHILD, PRESCHOOL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; MIDDLE AGED; PROGNOSIS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84923068229     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(14)00035-0     Document Type: Article

References (37)

1. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373: 1550-61.
2. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363: 2091-101.
3. Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367: 1487-96.
4. Socie G, Ritz J, Martin PJ. Current challenges in chronic graftversus- host disease. Biol Blood Marrow Transplant 2010; 16: S146-51.
5. Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2012; 18: 1150-63.
6. Deeg HJ. How I treat refractory acute GVHD. Blood 2007; 109: 4119-26.
7. Rowlings P, Przepiorka D, Klein J, et al. IBMTR severity Index for grading acute graft-versus-host disease: restrospective comparison with Glucksberg grade. Br J Haematol 1997; 97: 855-64.
8. Cahn JY, Klein JP, Lee SJ, et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greff e de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood 2005; 106: 1495-500.
9. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-28.
10. Nucci M, Andrade F, Vigorito A, et al. Infectious complications in patients randomized to receive allogeneic bone marrow or peripheral blood transplantation. Transpl Infect Dis 2003; 5: 167-73.
11. Holler E. Risk assessment in haematopoietic stem cell transplantation: GvHD prevention and treatment. Best Pract Res Clin Haematol 2007; 20: 281-94.
12. Campbell S, Sun CL, Kurian S, et al. Predictors of avascular necrosis of bone in long-term survivors of hematopoietic cell transplantation. Cancer 2009; 115: 4127-35.
13. Pidala J, Kim J, Kharfan-Dabaja MA, et al. Dysglycemia following glucocorticoid therapy for acute graft-versus-host disease adversely aff ects transplantation outcomes. Biol Blood Marrow Transplant 2011; 17: 239-48.
14. Arai S, Margolis J, Zahurak M, Anders V, Vogelsang GB. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002; 8: 155-60.
15. Levine JE, Logan B, Wu J, et al. Graft-versus-host disease treatment: predictors of survival. Biol Blood Marrow Transplant 2010; 16: 1693-99.
16. Westin JR, Saliba RM, De Lima M, et al. Steroid-refractory acute GVHD: Predictors and outcomes. Adv Hematol 2011; 2011: 601953.
17. Levine JE, Hogan WJ, Harris AC, et al. Improved accuracy of acute graft-versus-host disease staging among multiple centers. Best Pract Res Clin Haematol 2014; 27: 283-87.
18. Paczesny S, Krijanovski OI, Braun TM, et al. A biomarker panel for acute graft-versus-host disease. Blood 2009; 113: 273-78.
19. Paczesny S, Braun TM, Levine JE, et al. Elafi n is a biomarker of graft-versus-host disease of the skin. Sci Transl Med 2010; 2: 13ra2.
20. Ferrara JL, Harris AC, Greenson JK, et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood 2011; 118: 6702-08.
21. Vander Lugt MT, Braun TM, Hanash S, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med 2013; 369: 529-39.
22. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
23. Akaike H. New look at statistical-model identifi cation. IEEE T Automat Contr 1974; Ac19: 716-23.
24. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-54.
25. Levine JE, Logan BR, Wu J, et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood 2012; 119: 3854-60.
26. MacMillan ML, DeFor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment trials. Blood 2010; 115: 5412-17.
27. Mielcarek M, Storer BE, Boeckh M, et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood 2009; 113: 2888-94.
28. Johnson ML, Farmer ER. Graft-versus-host reactions in dermatology. J Am Acad Dermatol 1998; 38: 369-92.
29. Jagasia M, Arora M, Flowers ME, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012; 119: 296-307.
30. Hurley CK, Woolfrey A, Wang T, et al. The impact of HLA unidirectional mismatches on the outcome of myeloablative hematopoietic stem cell transplantation with unrelated donors. Blood 2013; 121: 4800-06.
31. Storb R, Gyurkocza B, Storer BE, et al. Graft-versus-host disease and graft-versus-tumor eff ects after allogeneic hematopoietic cell transplantation. J Clin Oncol 2013; 31: 1530-38.
32. Schmaltz C, Alpdogan O, Muriglan SJ, et al. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood 2003; 101: 2440-45.
33. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000; 95: 2754-59.
34. Pastorelli L, Garg RR, Hoang SB, et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci USA 2010; 107: 8017-22.
35. Ogawa H, Fukushima K, Naito H, et al. Increased expression of HIP/PAP and regenerating gene III in human infl ammatory bowel disease and a murine bacterial reconstitution model. Infl amm Bowel Dis 2003; 9: 162-70.
36. Ayuk F, Bussmann L, Zabelina T, et al. Serum albumin level predicts survival of patients with gastrointestinal acute graft-versushost disease after allogeneic stem cell transplantation. Ann Hematol 2014; 93: 855-61.
37. Magenau JM, Qin X, Tawara I, et al. Frequency of CD4(+)CD25(hi) FOXP3(+) regulatory t cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol Blood Marrow Transplant 2010; 16: 907-14.